JP2022051553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022051553A5 JP2022051553A5 JP2021151709A JP2021151709A JP2022051553A5 JP 2022051553 A5 JP2022051553 A5 JP 2022051553A5 JP 2021151709 A JP2021151709 A JP 2021151709A JP 2021151709 A JP2021151709 A JP 2021151709A JP 2022051553 A5 JP2022051553 A5 JP 2022051553A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- antibody variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 889
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 677
- 230000027455 binding Effects 0.000 claims description 193
- 239000000427 antigen Substances 0.000 claims description 179
- 102000036639 antigens Human genes 0.000 claims description 179
- 108091007433 antigens Proteins 0.000 claims description 179
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 208000015943 Coeliac disease Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 108010061711 Gliadin Proteins 0.000 description 50
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 46
- 108010068370 Glutens Proteins 0.000 description 38
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 35
- 239000004220 glutamic acid Substances 0.000 description 31
- 235000013922 glutamic acid Nutrition 0.000 description 31
- 125000000539 amino acid group Chemical group 0.000 description 23
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 22
- 235000021312 gluten Nutrition 0.000 description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 239000004472 Lysine Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000004475 Arginine Substances 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 108060006613 prolamin Proteins 0.000 description 8
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 108010016832 omega(2)-gliadin Proteins 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 108010025412 omega(1)-gliadin Proteins 0.000 description 5
- 101710204608 Avenin-3 Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010028930 invariant chain Proteins 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139889A JP2022172276A (ja) | 2020-09-18 | 2022-09-02 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157873 | 2020-09-18 | ||
| JP2020157873 | 2020-09-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139889A Division JP2022172276A (ja) | 2020-09-18 | 2022-09-02 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022051553A JP2022051553A (ja) | 2022-03-31 |
| JP2022051553A5 true JP2022051553A5 (enExample) | 2022-06-01 |
| JP7147030B2 JP7147030B2 (ja) | 2022-10-04 |
Family
ID=80739984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021151709A Active JP7147030B2 (ja) | 2020-09-18 | 2021-09-17 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
| JP2022139889A Pending JP2022172276A (ja) | 2020-09-18 | 2022-09-02 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139889A Pending JP2022172276A (ja) | 2020-09-18 | 2022-09-02 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11739153B2 (enExample) |
| EP (1) | EP4214236A4 (enExample) |
| JP (2) | JP7147030B2 (enExample) |
| KR (2) | KR20230116942A (enExample) |
| CN (3) | CN117801114A (enExample) |
| AR (1) | AR123537A1 (enExample) |
| AU (1) | AU2021343008B2 (enExample) |
| CA (1) | CA3192661A1 (enExample) |
| CL (1) | CL2023000765A1 (enExample) |
| CO (1) | CO2023003681A2 (enExample) |
| CR (1) | CR20230166A (enExample) |
| IL (1) | IL301326A (enExample) |
| MX (1) | MX2023002191A (enExample) |
| PE (1) | PE20231208A1 (enExample) |
| TW (2) | TW202402804A (enExample) |
| WO (1) | WO2022059766A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113950483B (zh) * | 2019-04-01 | 2025-08-05 | 中外制药株式会社 | 抗hla-dq2.5抗体 |
| KR20230116942A (ko) | 2020-09-18 | 2023-08-04 | 추가이 세이야쿠 가부시키가이샤 | 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 |
| CA3232707A1 (en) * | 2021-10-08 | 2023-04-13 | Kengo ARAI | Drug formulation of anti-hla-dq2.5 antibody |
| TW202333781A (zh) * | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| MXPA03009313A (es) | 2001-04-12 | 2004-11-12 | Academish Ziekenhuis Leiden | Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq. |
| MX2010008696A (es) | 2008-02-07 | 2010-08-30 | Amgen Inc | Composiciones de proteina estabilizadas. |
| AU2013204429B9 (en) | 2008-11-30 | 2017-01-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| WO2010141658A1 (en) | 2009-06-04 | 2010-12-09 | The Regent Of The University Of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| KR20130049196A (ko) | 2010-08-05 | 2013-05-13 | 에프. 호프만-라 로슈 아게 | 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질 |
| US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| WO2016202805A2 (en) | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| WO2018155692A1 (en) * | 2017-02-27 | 2018-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease |
| CN111225925B (zh) | 2017-10-03 | 2024-01-12 | 中外制药株式会社 | 抗hla-dq2.5抗体 |
| GB201802338D0 (en) * | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| CN113950483B (zh) | 2019-04-01 | 2025-08-05 | 中外制药株式会社 | 抗hla-dq2.5抗体 |
| KR20230116942A (ko) | 2020-09-18 | 2023-08-04 | 추가이 세이야쿠 가부시키가이샤 | 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 |
-
2021
- 2021-09-17 KR KR1020237024631A patent/KR20230116942A/ko active Pending
- 2021-09-17 EP EP21869449.5A patent/EP4214236A4/en active Pending
- 2021-09-17 TW TW112137009A patent/TW202402804A/zh unknown
- 2021-09-17 AR ARP210102585A patent/AR123537A1/es unknown
- 2021-09-17 CR CR20230166A patent/CR20230166A/es unknown
- 2021-09-17 MX MX2023002191A patent/MX2023002191A/es unknown
- 2021-09-17 TW TW110134821A patent/TWI820484B/zh active
- 2021-09-17 WO PCT/JP2021/034240 patent/WO2022059766A1/en not_active Ceased
- 2021-09-17 AU AU2021343008A patent/AU2021343008B2/en active Active
- 2021-09-17 KR KR1020217042982A patent/KR102559128B1/ko active Active
- 2021-09-17 CN CN202311813323.8A patent/CN117801114A/zh active Pending
- 2021-09-17 US US17/477,651 patent/US11739153B2/en active Active
- 2021-09-17 PE PE2023001173A patent/PE20231208A1/es unknown
- 2021-09-17 CA CA3192661A patent/CA3192661A1/en active Pending
- 2021-09-17 CN CN202180061976.8A patent/CN116096757B/zh active Active
- 2021-09-17 CN CN202311818773.6A patent/CN117801115A/zh active Pending
- 2021-09-17 IL IL301326A patent/IL301326A/en unknown
- 2021-09-17 JP JP2021151709A patent/JP7147030B2/ja active Active
-
2022
- 2022-09-02 JP JP2022139889A patent/JP2022172276A/ja active Pending
-
2023
- 2023-03-16 CL CL2023000765A patent/CL2023000765A1/es unknown
- 2023-03-23 CO CONC2023/0003681A patent/CO2023003681A2/es unknown
- 2023-07-05 US US18/346,975 patent/US20230357408A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022051553A5 (enExample) | ||
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| Riethmüller | Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on | |
| JP2021175391A5 (enExample) | ||
| JP2022512649A (ja) | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 | |
| JP2020186248A5 (enExample) | ||
| CN112272563A (zh) | 使用新颖抗pd-1序列的双特异性和单特异性抗体 | |
| JP2019533441A5 (enExample) | ||
| IL258822B2 (en) | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection | |
| JP2021159081A5 (enExample) | ||
| WO2015197582A1 (en) | Monomeric multispecific antigen binding proteins | |
| CA3007030A1 (en) | Heterodimeric antibodies that bind cd3 and psma | |
| WO2015197598A2 (en) | Multispecific antigen binding proteins | |
| AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
| WO2004005350A2 (fr) | Fragments fab mutans de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications | |
| JP2021507698A5 (enExample) | ||
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| CN118063620A (zh) | 双特异性抗体 | |
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| US20230074436A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| JP2019516785A (ja) | 親和性を操作した血清タンパク質担体結合ドメイン | |
| JP2023516925A (ja) | 新規の抗体 | |
| KR20240158351A (ko) | Cd3에 특이적인 탈면역화 항체 | |
| IL284317B2 (en) | Multispecific binding pseudo-fab proteins |